Business Context and Reporting Period
This Form 8-K Current Report, dated January 23, 2017, details the completion of a merger transaction between Leap Therapeutics, Inc. ("Leap") and Macrocure Ltd. (NASDAQ: MCUR). Following the merger, Macrocure became a wholly-owned subsidiary of Leap. Leap's common stock commenced trading on the NASDAQ Global Market on January 24, 2017, under the symbol "LPTX," while Macrocure's shares were delisted.
Key Financial Metrics and Transactions
- Equity Investment: HealthCare Ventures IX, L.P. ("HCV IX") invested $10.0 million in Leap by purchasing 1,010,225 shares of common stock at $9.90 per share.
- Merger Consideration: Macrocure shareholders received approximately 0.1815 shares of Leap common stock for each ordinary share held, plus cash in lieu of fractional shares valued at $9.90 per share.
- Cash Calculation: The exchange ratio was based on a final net cash calculation of $21.875 million as of the closing.
- Financial Statements: The filing does not provide current revenue, profit, cash flow, or debt metrics. Leap indicated that required financial statements of the acquired business and pro forma financial information will be filed by amendment no later than the 71st calendar day after the filing date.
Material Changes and Agreements
Several material definitive agreements were executed on January 23, 2017:
- Royalty Agreement: Leap entered into a Royalty Agreement with Leap Shareholder Royalty Vehicle, LLC, and a related Letter Agreement outlining tax treatment for royalty rights.
- Registration Rights: A Registration Rights Agreement was signed with Pre-Merger Stockholders and certain Macrocure shareholders.
- Termination: The Amended and Restated Stockholders' Agreement dated December 10, 2015, was terminated effective upon the execution of the new Registration Rights Agreement.
- Corporate Structure: Leap filed a Third Amended and Restated Certificate of Incorporation, authorizing 100,000,000 shares of common stock, eliminating previous preferred stock series, and effecting a 1-for-19.86754 reverse stock split.
Outlook, Risks, and Governance Changes
The filing focuses on the structural completion of the merger rather than forward-looking financial guidance. Key governance changes include the establishment of a classified board of directors with staggered three-year terms and the elimination of the ability for stockholders to take action by written consent. Directors may now only be removed for cause by a two-thirds vote. The filing notes that Macrocure expects to cease filing reports with the SEC approximately 10 days post-closing.
Investor Verification Checklist
- Verify the final pro forma financial statements and financial statements of Macrocure, expected to be filed within 71 days of this report.
- Review the full text of the Royalty Agreement (Exhibit 10.1) to understand future royalty obligations and tax implications.
- Confirm the trading status and liquidity of the new "LPTX" ticker on NASDAQ.
- Examine the impact of the 1-for-19.86754 reverse stock split on existing share counts and ownership percentages.
- Monitor the delisting process of Macrocure shares and the termination of its Exchange Act registration.